文献速递质量管理与危急值临床生化

最小复检间隔的十年实践:基于证据的推荐应用回顾

Minimum retesting intervals in practice: 10 years experience.
PubMed 文献 · Clin Chem Lab Med · 2020-09-07

该文回顾2011年ACB最小复检间隔(MRI)推荐发布至2020年的应用情况,并与2000-2010年数据比较。共纳入31项研究(2000-2010年4项,2011-2020年27项)。不满足MRI的检测比例从4.6%(203,104/4,425,311)升至11.8%(2,691,591/22,777,288)。报告预测节省的20项研究中,14.3%检测被取消,总节省2.9百万欧元或2.77欧元/检测。最常被拒检项目为HbA1c,占拒检总数近四分之一。27项研究中13项采用ACB推荐。结论认为MRI是成熟、安全、可持续的需求管理工具。

要点

  • MRI推荐实施后不满足MRI的检测比例从4.6%升至11.8%。
  • 报告预测节省的研究中14.3%检测被取消,节省2.9百万欧元。
  • HbA1c是最常被拒检项目,占拒检总数近四分之一。

核心结论

  • MRI已成为识别和管理不适当检测的成熟、安全且可持续的需求管理工具。
  • 基于证据的共识推荐支持MRI在全球多种医疗环境中采用并促进实验室实践协调。

研究设计与样本

  • 多来源文献检索,纳入2000-2010年(推荐前)和2011-2020年(推荐后)报告MRI用于管理或识别不适当检测的研究。
  • 共纳入31项符合标准的研究,其中2000-2010年4项,2011-2020年27项。

主要发现

  • 2000-2010年不满足MRI的检测比例为4.6%(203,104/4,425,311),2011-2020年升至11.8%(2,691,591/22,777,288)。
  • 2011-2020年报告预测节省的20项研究中,14.3%检测被取消(1,079,972/750,580),总节省2.9百万欧元或2.77欧元/检测(原文数值照录)。
  • 最常被拒检项目为血红蛋白A1c(HbA1c),占拒检总数近四分之一。
  • 27项研究中13项使用了ACB推荐。

临床怎么用

  • MRI可作为实验室需求管理工具,用于识别和减少过度使用的检测项目。
  • ACB证据推荐支持在多种医疗环境中实施MRI以协调实验室实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Minimum retesting intervals (MRI) are a popular demand management solution for the identification and reduction of over-utilized tests. In 2011 Association of Clinical Biochemistry and Laboratory Medicines (ACB) published evidence-based recommendations for the use of MRI. AIM: The aim of the paper was to review the use of MRI over the period since the introduction of these recommendations in 2011 to 2020 and compare it to previous published data between 2000-2010. METHODS: A multi-source literature search was performed to identify studies that reported the use of a MRI in the management or identification of inappropriate testing between the years prior to (2000-2010) and after implementation (2011-2020) of these recommendations. RESULTS: 31 studies were identified which met the acceptance criteria (2000-2010 n=4, 2011-2020 n=27). Between 2000 and 2010 4.6% of tests (203,104/4,425,311) were identified as failing a defined MRI which rose to 11.8% of tests (2,691,591/22,777,288) in the 2011-2020 period. For those studies between 2011 and 2020 reporting predicted savings (n=20), 14.3% of tests (1,079,972/750,580) were cancelled, representing a total saving of 2.9 M Euros or 2.77 Euro/test. The most popular rejected test was Haemoglobin A1c which accounted for nearly a quarter of the total number of rejected tests. 13 out 27 studies used the ACB recommendations. CONCLUSIONS: MRI are now an established, safe and sustainable demand management tool for the identification and management of inappropriate testing. Evidence based consensus recommendations have supported the adoption of this demand management tool into practice across multiple healthcare settings globally and harmonizing laboratory practice.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Lang T. Minimum retesting intervals in practice: 10 years experience. Clin Chem Lab Med. 2020. PMID: 32892171. doi:10.1515/cclm-2020-0660

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。